A biodegradable PLA composite film incorporating organically modified montmorillonite (OMMT) nanoclays to dramatically improve moisture barrier performance. Designed as a skin layer for sustainable packaging, the technology leverages tortuous path effects from aligned OMMT nanoplatelets to reduce water vapor transmission while maintaining biodegradability and process compatibility with standard PLA extrusion.
This solution addresses a critical limitation of polylactic acid (PLA) packaging films—poor moisture barrier performance—by compositing PLA with organically modified montmorillonite (OMMT) nanoclays. The resulting nanocomposite film is biodegradable and compatible with standard PLA extrusion and co-extrusion processes, making it suitable as a skin layer to enhance moisture barrier performance in multilayer packaging structures. By tuning OMMT content and orientation, the film can significantly reduce water vapor transmission rate (WVTR), enabling PLA to compete with conventional petroleum-based barrier films in food, consumer goods, and industrial packaging applications.
Core approach:
Key features:
Validation methods:
This technology is at an early-to-mid research stage (TRL 3–4). Prior published work has demonstrated proof-of-concept barrier improvements in solution-cast PLA/OMMT films. Future validation will focus on translating these results to extruded films by systematically examining the effects of OMMT content and orientation on moisture barrier performance. The team will optimize extrusion conditions to control OMMT morphology within the film and validate performance using standardized ASTM test methods for both barrier properties and biodegradability. Successful completion would position the technology for pilot-scale trials and partnership with packaging manufacturers.
Georgia Institute of Technology is a large, technology‑focused public research university in Atlanta with a strong applied research culture. Industry engages through the Georgia Tech Research Institute for contract R&D, a Midtown innovation district with co‑located corporate labs, and a statewide manufacturing extension to support scale‑up. A long‑standing partnership with a major academic medical center enables clinical translation, and a large co‑op program delivers a steady talent pipeline. Research is backed by competitive federal funding from NSF, NIH, DOE, DoD, and NASA. Technology commercialization is managed by the Georgia Tech Research Corporation, with dedicated licensing, corporate contracting, and startup support.